PURPOSE: To evaluate the recurrence of uveitis after discontinuation of infliximab once control of inflammation is achieved. METHODS: A retrospective cohort study was conducted of patients seen at the Proctor Foundation between 1998 and 2010 who discontinued infliximab after achieving corticosteroid-sparing control by Standardization of Uveitis Nomenclature criteria. The main outcome was the proportion of patients who had a relapse of uveitis. RESULTS: Eighteen patients attempted to discontinue infliximab after achieving control of inflammation, and 11 patients had a relapse. Median time to relapse was 603 days (95% CI: 85-1461 days). Patients with juvenile idiopathic arthritis (JIA)-associated uveitis (n = 4) relapsed faster (median time to relapse: 76 days, p = 0.002) compared with patients who did not have JIA-associated uveitis (median = 1169 days). CONCLUSIONS: The majority of patients who achieved control of inflammation on infliximab had a recurrence after discontinuing therapy. Patients with JIA experienced recurrence faster compared to other patients.
PURPOSE: To evaluate the recurrence of uveitis after discontinuation of infliximab once control of inflammation is achieved. METHODS: A retrospective cohort study was conducted of patients seen at the Proctor Foundation between 1998 and 2010 who discontinued infliximab after achieving corticosteroid-sparing control by Standardization of Uveitis Nomenclature criteria. The main outcome was the proportion of patients who had a relapse of uveitis. RESULTS: Eighteen patients attempted to discontinue infliximab after achieving control of inflammation, and 11 patients had a relapse. Median time to relapse was 603 days (95% CI: 85-1461 days). Patients with juvenile idiopathic arthritis (JIA)-associated uveitis (n = 4) relapsed faster (median time to relapse: 76 days, p = 0.002) compared with patients who did not have JIA-associated uveitis (median = 1169 days). CONCLUSIONS: The majority of patients who achieved control of inflammation on infliximab had a recurrence after discontinuing therapy. Patients with JIA experienced recurrence faster compared to other patients.
Authors: Sheila T Angeles-Han; Mindy S Lo; Lauren A Henderson; Melissa A Lerman; Leslie Abramson; Ashley M Cooper; Miriam F Parsa; Lawrence S Zemel; Tova Ronis; Timothy Beukelman; Erika Cox; H Nida Sen; Gary N Holland; Hermine I Brunner; Andrew Lasky; C Egla Rabinovich Journal: Arthritis Care Res (Hoboken) Date: 2019-04 Impact factor: 4.794
Authors: Nisha R Acharya; Caleb D Ebert; Nicole K Kelly; Travis C Porco; Athimalaipet V Ramanan; Benjamin F Arnold Journal: Trials Date: 2020-10-27 Impact factor: 2.279